drugset
Drugs / MRKAd5 HIV-1 gag/pol/nef
last change Oct 2010 re-read 3 minutes ago

MRKAd5 HIV-1 gag/pol/nef

Vaccine

Developed for
HIV infectious disease
Investigated by
Acute Infection and Early Disease Research Program · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

today NCT00183261 · Ph 2
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00183261 Mar 2006 → Aug 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MRKAd5 HIV-1 gag/pol/nef ClinicalTrials.gov intervention name — accepted as the source's own label NCT00183261 ↗
Modality Vaccine “HIV vaccine MRKAd5 HIV-1 gag/pol/nef” NCT00183261 ↗
Route Intramuscular “1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly” NCT00183261 ↗